BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

415 related articles for article (PubMed ID: 29178021)

  • 1. Epigenetic Drivers in Pediatric Medulloblastoma.
    Roussel MF; Stripay JL
    Cerebellum; 2018 Feb; 17(1):28-36. PubMed ID: 29178021
    [TBL] [Abstract][Full Text] [Related]  

  • 2. SMARCA4/Brg1 coordinates genetic and epigenetic networks underlying Shh-type medulloblastoma development.
    Shi X; Wang Q; Gu J; Xuan Z; Wu JI
    Oncogene; 2016 Nov; 35(44):5746-5758. PubMed ID: 27065321
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Novel Method for Rapid Molecular Subgrouping of Medulloblastoma.
    Gómez S; Garrido-Garcia A; Garcia-Gerique L; Lemos I; Suñol M; de Torres C; Kulis M; Pérez-Jaume S; Carcaboso ÁM; Luu B; Kieran MW; Jabado N; Kozlenkov A; Dracheva S; Ramaswamy V; Hovestadt V; Johann P; Jones DTW; Pfister SM; Morales La Madrid A; Cruz O; Taylor MD; Martin-Subero JI; Mora J; Lavarino C
    Clin Cancer Res; 2018 Mar; 24(6):1355-1363. PubMed ID: 29351917
    [No Abstract]   [Full Text] [Related]  

  • 4. The micro-RNA 199b-5p regulatory circuit involves Hes1, CD15, and epigenetic modifications in medulloblastoma.
    Andolfo I; Liguori L; De Antonellis P; Cusanelli E; Marinaro F; Pistollato F; Garzia L; De Vita G; Petrosino G; Accordi B; Migliorati R; Basso G; Iolascon A; Cinalli G; Zollo M
    Neuro Oncol; 2012 May; 14(5):596-612. PubMed ID: 22411914
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Transitioning from genotypes to epigenotypes: why the time has come for medulloblastoma epigenomics.
    Batora NV; Sturm D; Jones DT; Kool M; Pfister SM; Northcott PA
    Neuroscience; 2014 Apr; 264():171-85. PubMed ID: 23876321
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Restoration of miR-193a expression is tumor-suppressive in MYC amplified Group 3 medulloblastoma.
    Bharambe HS; Joshi A; Yogi K; Kazi S; Shirsat NV
    Acta Neuropathol Commun; 2020 May; 8(1):70. PubMed ID: 32410663
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular Stratification of Medulloblastoma: Clinical Outcomes and Therapeutic Interventions.
    Sursal T; Ronecker JS; Dicpinigaitis AJ; Mohan AL; Tobias ME; Gandhi CD; Jhanwar-Uniyal M
    Anticancer Res; 2022 May; 42(5):2225-2239. PubMed ID: 35489737
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Epigenetic regulation in medulloblastoma pathogenesis revealed by genetically engineered mouse models.
    Shiraishi R; Kawauchi D
    Cancer Sci; 2021 Aug; 112(8):2948-2957. PubMed ID: 34050694
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Medulloblastoma molecular dissection: the way toward targeted therapy.
    Remke M; Ramaswamy V; Taylor MD
    Curr Opin Oncol; 2013 Nov; 25(6):674-81. PubMed ID: 24076581
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Downregulation of ARID1B, a tumor suppressor in the WNT subgroup medulloblastoma, activates multiple oncogenic signaling pathways.
    Deogharkar A; Singh SV; Bharambe HS; Paul R; Moiyadi A; Goel A; Shetty P; Sridhar E; Gupta T; Jalali R; Goel N; Gadewal N; Muthukumar S; Shirsat NV
    Hum Mol Genet; 2021 Aug; 30(18):1721-1733. PubMed ID: 33949667
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dissecting the genomic complexity underlying medulloblastoma.
    Jones DT; Jäger N; Kool M; Zichner T; Hutter B; Sultan M; Cho YJ; Pugh TJ; Hovestadt V; Stütz AM; Rausch T; Warnatz HJ; Ryzhova M; Bender S; Sturm D; Pleier S; Cin H; Pfaff E; Sieber L; Wittmann A; Remke M; Witt H; Hutter S; Tzaridis T; Weischenfeldt J; Raeder B; Avci M; Amstislavskiy V; Zapatka M; Weber UD; Wang Q; Lasitschka B; Bartholomae CC; Schmidt M; von Kalle C; Ast V; Lawerenz C; Eils J; Kabbe R; Benes V; van Sluis P; Koster J; Volckmann R; Shih D; Betts MJ; Russell RB; Coco S; Tonini GP; Schüller U; Hans V; Graf N; Kim YJ; Monoranu C; Roggendorf W; Unterberg A; Herold-Mende C; Milde T; Kulozik AE; von Deimling A; Witt O; Maass E; Rössler J; Ebinger M; Schuhmann MU; Frühwald MC; Hasselblatt M; Jabado N; Rutkowski S; von Bueren AO; Williamson D; Clifford SC; McCabe MG; Collins VP; Wolf S; Wiemann S; Lehrach H; Brors B; Scheurlen W; Felsberg J; Reifenberger G; Northcott PA; Taylor MD; Meyerson M; Pomeroy SL; Yaspo ML; Korbel JO; Korshunov A; Eils R; Pfister SM; Lichter P
    Nature; 2012 Aug; 488(7409):100-5. PubMed ID: 22832583
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Epigenetic regulation in medulloblastoma.
    Yi J; Wu J
    Mol Cell Neurosci; 2018 Mar; 87():65-76. PubMed ID: 29269116
    [TBL] [Abstract][Full Text] [Related]  

  • 13. BarTeL, a Genetically Versatile, Bioluminescent and Granule Neuron Precursor-Targeted Mouse Model for Medulloblastoma.
    Shackleford GM; Shi XH; Swanson KS; Mahdi MY; Gonzalez-Gomez I; Asgharzadeh S; D'Apuzzo M; Erdreich-Epstein A; Moats RA
    PLoS One; 2016; 11(6):e0156907. PubMed ID: 27310018
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Medulloblastoma epigenetics and the path to clinical innovation.
    Haltom AR; Toll SA; Cheng D; Maegawa S; Gopalakrishnan V; Khatua S
    J Neurooncol; 2020 Oct; 150(1):35-46. PubMed ID: 32816225
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Downregulation of miR-204 expression defines a highly aggressive subset of Group 3/Group 4 medulloblastomas.
    Bharambe HS; Paul R; Panwalkar P; Jalali R; Sridhar E; Gupta T; Moiyadi A; Shetty P; Kazi S; Deogharkar A; Masurkar S; Yogi K; Kunder R; Gadewal N; Goel A; Goel N; Chinnaswamy G; Ramaswamy V; Shirsat NV
    Acta Neuropathol Commun; 2019 Apr; 7(1):52. PubMed ID: 30944042
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Outcomes by Clinical and Molecular Features in Children With Medulloblastoma Treated With Risk-Adapted Therapy: Results of an International Phase III Trial (SJMB03).
    Gajjar A; Robinson GW; Smith KS; Lin T; Merchant TE; Chintagumpala M; Mahajan A; Su J; Bouffet E; Bartels U; Schechter T; Hassall T; Robertson T; Nicholls W; Gururangan S; Schroeder K; Sullivan M; Wheeler G; Hansford JR; Kellie SJ; McCowage G; Cohn R; Fisher MJ; Krasin MJ; Stewart CF; Broniscer A; Buchhalter I; Tatevossian RG; Orr BA; Neale G; Klimo P; Boop F; Srinivasan A; Pfister SM; Gilbertson RJ; Onar-Thomas A; Ellison DW; Northcott PA
    J Clin Oncol; 2021 Mar; 39(7):822-835. PubMed ID: 33405951
    [TBL] [Abstract][Full Text] [Related]  

  • 17. YB-1 is elevated in medulloblastoma and drives proliferation in Sonic hedgehog-dependent cerebellar granule neuron progenitor cells and medulloblastoma cells.
    Dey A; Robitaille M; Remke M; Maier C; Malhotra A; Gregorieff A; Wrana JL; Taylor MD; Angers S; Kenney AM
    Oncogene; 2016 Aug; 35(32):4256-68. PubMed ID: 26725322
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Medulloblastoma: Molecular Classification-Based Personal Therapeutics.
    Archer TC; Mahoney EL; Pomeroy SL
    Neurotherapeutics; 2017 Apr; 14(2):265-273. PubMed ID: 28386677
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genetic Markers as Predictors for Response to Treatment and Possible Therapeutic Targets in Medulloblastoma.
    Pérez-Pineda PL; Ortiz-Butrón R; Pérez-De Marcos JC; Hernández-Regino LM; Zapata-Tarrés MM; Torres-Espíndola LM
    CNS Neurol Disord Drug Targets; 2023; 22(5):634-642. PubMed ID: 35579144
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The genetic landscape of the childhood cancer medulloblastoma.
    Parsons DW; Li M; Zhang X; Jones S; Leary RJ; Lin JC; Boca SM; Carter H; Samayoa J; Bettegowda C; Gallia GL; Jallo GI; Binder ZA; Nikolsky Y; Hartigan J; Smith DR; Gerhard DS; Fults DW; VandenBerg S; Berger MS; Marie SK; Shinjo SM; Clara C; Phillips PC; Minturn JE; Biegel JA; Judkins AR; Resnick AC; Storm PB; Curran T; He Y; Rasheed BA; Friedman HS; Keir ST; McLendon R; Northcott PA; Taylor MD; Burger PC; Riggins GJ; Karchin R; Parmigiani G; Bigner DD; Yan H; Papadopoulos N; Vogelstein B; Kinzler KW; Velculescu VE
    Science; 2011 Jan; 331(6016):435-9. PubMed ID: 21163964
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.